Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
The Journal of Biological Chemistry
|
August 5, 1991
p185HER2 signal transduction in breast cancer cells
G K Scott, J M Dodson, P A Montgomery, et al.
Gene Therapy
|
December 13, 2005
Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery
M E Hayes, D C Drummond, D B Kirpotin, et al.
Molecular Pharmacology
|
June 1, 1990
Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers
C C Benz, M A Keniry, J M Ford, et al.
Oncogene
|
April 3, 1997
ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis
C H Chang, G K Scott, W L Kuo, et al.
Oncogene
|
October 31, 1997
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer
C C Benz, R C O'Hagan, B Richter, et al.
Molecular Pharmaceutics
|
December 5, 2006
Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation
M E Hayes, D C Drummond, K Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Breast Cancer Research and Treatment
|
January 24, 2002
Expedition inspiration consensus 2001
C C Benz, L Hilakivi-Clarke, S Conzen, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
The Journal of Biological Chemistry
|
August 5, 1991
p185HER2 signal transduction in breast cancer cells
G K Scott, J M Dodson, P A Montgomery, et al.
Gene Therapy
|
December 13, 2005
Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery
M E Hayes, D C Drummond, D B Kirpotin, et al.
Molecular Pharmacology
|
June 1, 1990
Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers
C C Benz, M A Keniry, J M Ford, et al.
Oncogene
|
April 3, 1997
ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis
C H Chang, G K Scott, W L Kuo, et al.
Oncogene
|
October 31, 1997
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer
C C Benz, R C O'Hagan, B Richter, et al.
Molecular Pharmaceutics
|
December 5, 2006
Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation
M E Hayes, D C Drummond, K Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Seminars in Oncology
|
September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
J Baselga, D Tripathy, J Mendelsohn, et al.
Breast Cancer Research and Treatment
|
January 24, 2002
Expedition inspiration consensus 2001
C C Benz, L Hilakivi-Clarke, S Conzen, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
Page
of 8